Takeda's candesartan successor, azilsartan, moves forward in hypertension
This article was originally published in Scrip
Executive Summary
There has been some positive news for Takeda's late-stage pipeline with the start of Phase III hypertension trials in Japan for the company's candesartan successor, azilsartan (TAK-536).